Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedFeb 07, 2026
DataAggregated Company Financials
Companies59
  • 7D2.8%
  • 3M-3.4%
  • 1Y3.9%
  • YTD-11.3%

In the last week, the Pharma industry is up 2.8%, with Curaleaf Holdings leading the way, up 8.6%. In the same time, Aurora Cannabis was down 13%. In the last 12 months, the industry was up 3.9%. Earnings are forecast to grow by 59% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 07 Feb 2026CA$14.2bCA$11.2b-CA$1,941,215,725.6316x-7.3x1.3x
Mon, 05 Jan 2026CA$16.5bCA$11.2b-CA$1,942,561,183.2216.6x-8.5x1.5x
Wed, 03 Dec 2025CA$13.9bCA$11.4b-CA$1,932,303,116.3514.5x-7.2x1.2x
Fri, 31 Oct 2025CA$16.0bCA$11.2b-CA$2,037,273,211.5433.3x-7.9x1.4x
Sun, 28 Sep 2025CA$15.3bCA$11.3b-CA$2,043,530,996.5934x-7.5x1.4x
Tue, 26 Aug 2025CA$17.0bCA$11.9b-CA$2,550,325,025.8237.3x-6.7x1.4x
Thu, 24 Jul 2025CA$11.1bCA$11.7b-CA$2,523,026,867.5616.9x-4.4x0.9x
Sat, 21 Jun 2025CA$9.6bCA$11.7b-CA$2,527,295,149.1518x-3.8x0.8x
Mon, 19 May 2025CA$9.1bCA$10.3b-CA$2,189,505,861.0817.5x-4.2x0.9x
Wed, 16 Apr 2025CA$9.0bCA$12.1b-CA$2,582,499,665.1419.3x-3.5x0.7x
Fri, 14 Mar 2025CA$10.9bCA$12.4b-CA$2,655,650,103.5220x-4.1x0.9x
Sun, 09 Feb 2025CA$12.7bCA$12.1b-CA$2,206,618,127.1820.5x-5.7x1x
Tue, 07 Jan 2025CA$13.6bCA$12.1b-CA$2,409,704,539.8428.8x-5.6x1.1x
Thu, 05 Dec 2024CA$13.9bCA$11.9b-CA$2,571,108,625.1322.1x-5.4x1.2x
Sat, 02 Nov 2024CA$18.3bCA$11.9b-CA$2,723,751,968.2718.5x-6.7x1.5x
Mon, 30 Sep 2024CA$18.4bCA$11.6b-CA$2,688,870,642.7527.7x-6.8x1.6x
Wed, 28 Aug 2024CA$18.6bCA$11.5b-CA$2,725,385,465.7222.1x-6.8x1.6x
Fri, 26 Jul 2024CA$20.1bCA$11.8b-CA$3,210,246,231.9220.3x-6.3x1.7x
Sun, 23 Jun 2024CA$19.6bCA$11.8b-CA$3,231,300,250.6417.2x-6.1x1.7x
Tue, 21 May 2024CA$25.0bCA$11.9b-CA$3,482,874,663.9613.8x-7.2x2.1x
Thu, 18 Apr 2024CA$24.2bCA$12.0b-CA$3,479,051,905.128.7x-7x2x
Sat, 16 Mar 2024CA$19.2bCA$11.9b-CA$3,499,996,583.818.9x-5.5x1.6x
Mon, 12 Feb 2024CA$23.3bCA$11.9b-CA$6,801,390,350.3312.1x-3.4x2x
Wed, 10 Jan 2024CA$19.3bCA$12.3b-CA$6,742,078,090.0010x-2.9x1.6x
Fri, 08 Dec 2023CA$19.7bCA$12.4b-CA$6,785,821,946.008.5x-2.9x1.6x
Sun, 05 Nov 2023CA$16.1bCA$12.4b-CA$7,313,471,152.0011.6x-2.2x1.3x
Tue, 03 Oct 2023CA$20.0bCA$12.4b-CA$7,336,437,455.0015.5x-2.7x1.6x
Thu, 31 Aug 2023CA$15.5bCA$12.9b-CA$7,869,696,339.0013.9x-2x1.2x
Sat, 29 Jul 2023CA$14.3bCA$13.2b-CA$9,713,979,724.0012.4x-1.5x1.1x
Mon, 26 Jun 2023CA$14.7bCA$13.1b-CA$9,509,166,656.0013.7x-1.5x1.1x
Wed, 24 May 2023CA$15.3bCA$13.3b-CA$10,449,908,430.0010x-1.5x1.1x
Fri, 21 Apr 2023CA$15.0bCA$13.3b-CA$9,955,452,188.0010.8x-1.5x1.1x
Sun, 19 Mar 2023CA$18.1bCA$13.9b-CA$10,109,313,585.008.7x-1.8x1.3x
Tue, 14 Feb 2023CA$19.3bCA$13.5b-CA$10,280,405,767.0010x-1.9x1.4x
Price to Earnings Ratio

-1.9x


Total Market Cap: CA$19.3bTotal Earnings: -CA$10,280,405,767.00Total Revenue: CA$13.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -4.8x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market2.07%
Healthcare2.20%
Pharma2.77%
Pharma2.77%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CURA Curaleaf HoldingsCA$3.278.6%
+CA$201.2m		42.8%PS1.5x
GTII Green Thumb IndustriesCA$9.899.3%
+CA$194.1m		-3.7%PE38.4x
CRON Cronos GroupCA$3.605.9%
+CA$76.6m		29.5%PE28x
TSND TerrAscendCA$0.927.0%
+CA$18.4m		-1.1%PS0.7x
HITI High TideCA$3.225.9%
+CA$15.8m		-20.7%PS0.5x

Latest News

TRUL
CA$9.48
Trulieve Cannabis
7D
0.9%
1Y
39.8%
ACB
CA$4.77
Aurora Cannabis
7D
-13.4%
1Y
-44.7%

ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead

Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.
GTII
CA$9.89
Green Thumb Industries
7D
9.3%
1Y
-3.7%
CURA
CA$3.27
Curaleaf Holdings
7D
8.6%
1Y
42.8%

CURA: Expanded Retail Footprint And Higher Guidance Will Support Bullish Re Rating

Analysts have trimmed their price target on Curaleaf Holdings to about US$4.37 from roughly US$4.40, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Curaleaf opened an adult use store adjacent to its existing medical dispensary at 829 Hogan Rd., Bangor, Maine, bringing its retail footprint to five locations in Maine and 161 locations across the United States (Key Developments).
TSND
CA$0.92
TerrAscend
7D
7.0%
1Y
-1.1%

TSND: Union Chill Deal Will Drive Future Retail And Margin Upside

Analysts have trimmed their price target on TerrAscend to about US$1.25 from roughly US$1.50, citing reduced revenue growth expectations and a lower future P/E multiple, partly offset by higher projected profit margins. What's in the News TerrAscend closed its previously announced transaction with Union Chill Cannabis Company LLC, adding a high performing dispensary in Hunterdon County, New Jersey, and bringing its retail footprint in the state to four dispensaries (Key Developments).
OGI
CA$2.10
Organigram Global
7D
3.4%
1Y
-11.8%
CRON
CA$3.60
Cronos Group
7D
5.9%
1Y
29.5%
HITI
CA$3.22
High Tide
7D
5.9%
1Y
-20.7%
INNO
CA$6.32
InnoCan Pharma
7D
-33.3%
1Y
-47.4%
VREO
CA$0.72
Vireo Growth
7D
-4.0%
1Y
9.1%
CRDL
CA$1.37
Cardiol Therapeutics
7D
7.0%
1Y
-28.3%
SKNY
CA$1.37
LIR Life Sciences
7D
-32.5%
1Y
n/a
NGEN
CA$5.35
NervGen Pharma
7D
-1.7%
1Y
87.1%
IAN
CA$0.005
iAnthus Capital Holdings
7D
-50.0%
1Y
-50.0%

iAnthus Capital Holdings, Inc.'s (CSE:IAN) 50% Dip In Price Shows Sentiment Is Matching Revenues

Dec 28
iAnthus Capital Holdings, Inc.'s (CSE:IAN) 50% Dip In Price Shows Sentiment Is Matching Revenues
XLY
CA$0.13
Auxly Cannabis Group
7D
-3.7%
1Y
136.4%
FNT.U
US$0.025
FLUENT
7D
-37.5%
1Y
-64.3%